Table 1.
Baseline characteristics sorted for patients with and without clinical benefit.
| Characteristic, N (%) | N (%) | Number of Patients (n = 76) | ||
|---|---|---|---|---|
| Clinical Benefit 1 (n = 40) | No Clinical Benefit 1 (n = 36) | Difference | ||
| Age at diagnosis | p = 0.53 | |||
| Median (range) | 66.3 (46–83) | 65.2 (42–81) | ||
| Gender | p = 0.18 | |||
| Male | 39 (97.5) | 32 (88.9) | ||
| Female | 1 (2.5) | 4 (11.1) | ||
| Location primary tumor | p = 0.84 | |||
| Parotid | 28 (70.0) | 24 (66.7) | ||
| Sublingual | 0 (0) | 0 (0) | ||
| Submandibular | 9 (22.5) | 10 (27.8) | ||
| Minor | 3 (7.5) | 2 (5.6) | ||
| HER2 status 2 | p = 0.075 | |||
| Positive | 7 (17.5) | 13 (36.1) | ||
| Negative | 33 (82.5) | 23 (63.9) | ||
| HER2 IHC | p = 0.071 | |||
| 0 | 9 (22.5) | 9 (25.0) | ||
| 1+ | 17 (42.5) | 9 (25.0) | ||
| 2+ | 9 (22.5) | 5 (13.9) | ||
| 3+ | 5 (12.5) | 13 (36.1) | ||
| T-stage at diagnosis | p = 1.0 | |||
| 1–2 | 18 (45.0) | 15 (41.7) | ||
| 3–4 | 22 (55.0) | 20 (55.6) | ||
| Unknown | 0 (0) | 1 (2.7) | ||
| N-stage at diagnosis | p = 0.34 | |||
| 0 | 16 (40.0) | 10 (27.8) | ||
| 1–2 | 24 (60.0) | 26 (72.2) | ||
| M-stage at diagnosis | p = 0.36 | |||
| 0 | 32 (80.0) | 32 (88.9) | ||
| 1 | 8 (20.0) | 4 (11.1) | ||
| R/M | p = 0.41 | |||
| Locally advanced/recurrent | 7 (17.5) | 3 (8.3) | ||
| Metastatic | 27 (67.5) | 27 (75.0) | ||
| Both | 6 (15.0) | 6 (16.7) | ||
| Underwent surgery | p = 1.0 | |||
| Yes | 34 (85.0) | 31 (86.1) | ||
| No | 6 (15.0) | 5 (13.9) | ||
| Postoperative radiotherapy | p = 1.0 | |||
| Yes | 16 (40.0) | 15 (41.7) | ||
| No | 24 (60.0) | 21 (58.3) | ||
| CAB as first line | p = 0.43 | |||
| Yes | 28 (70.0) | 29 (80.6) | ||
| No | 12 (30.0) | 7 (19.4) | ||
| Post-CAB systemic treatment | p = 0.094 | |||
| Yes | 22 (55.0) | 27 (75.0) | ||
| No | 18 (45) | 9 (25.0) | ||
| Post-CAB anti-HER2 | p = 0.01 | |||
| Yes | 2 (5.0) | 10 (27.8) | ||
| No | 38 (95.0) | 26 (72.2) | ||
| Post-CAB chemotherapy | p < 0.001 | |||
| Yes | 9 (22.5) | 24 (66.7) | ||
| No | 31 (77.5) | 12 (33.3) | ||
| Post-CAB platinum- based treatment | p = 0.10 | |||
| Yes | 6 (15.0) | 12 (33.3) | ||
| No | 34 (85.0) | 24 (66.7) | ||
Abbreviations: HER2: human epidermal growth factor receptor 2; T: tumor; N: nodal; M: metastasis; R/M: locally advanced, recurrent, or metastatic; CAB: combined androgen blockade. 1 Clinical benefit: CR, PR, or SD ≥6 months. 2 HER2 status according to ASCO/CAP guidelines.